HomeBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Nakaraang pagsara
CHF 41.15
Sakop ng araw
CHF 40.60 - CHF 41.45
Sakop ng taon
CHF 32.00 - CHF 49.00
Market cap
540.62M CHF
Average na Volume
17.18K
P/E ratio
47.10
Dividend yield
-
Primary exchange
SWX
Mga balita tungkol sa merkado
NVDA
1.47%
Mga Financial
Income Statement
Kita
Net na kita
(CHF) | Dis 2023info | Y/Y na pagbabago |
---|---|---|
Kita | 36.36M | -19.30% |
Gastos sa pagpapatakbo | 7.96M | 12.34% |
Net na kita | -10.69M | -187.82% |
Net profit margin | -29.41 | -208.81% |
Kita sa bawat share | — | — |
EBITDA | -7.88M | -152.08% |
Aktuwal na % ng binabayarang buwis | 0.08% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(CHF) | Dis 2023info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 59.93M | -29.21% |
Kabuuang asset | 173.29M | -21.53% |
Kabuuang sagutin | 183.29M | -24.12% |
Kabuuang equity | -10.00M | — |
Natitirang share | 12.00M | — |
Presyo para makapag-book | -49.58 | — |
Return on assets | -11.81% | — |
Return on capital | -17.26% | — |
Cash Flow
Net change in cash
(CHF) | Dis 2023info | Y/Y na pagbabago |
---|---|---|
Net na kita | -10.69M | -187.82% |
Cash mula sa mga operasyon | -3.81M | -210.31% |
Cash mula sa pag-invest | -322.50K | -100.69% |
Cash mula sa financing | -20.11M | -4.52% |
Net change in cash | -24.31M | -178.80% |
Malayang cash flow | -4.62M | -154.24% |
Tungkol
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
CEO
Itinatag
Okt 2000
Website
Mga Empleyado
147